Stockholm, Sweden, March 26, 2021. Egetis Therapeutics AB (publ) (ticker: EGTX) today announced that the nomination committee proposes that Mats Blom is appointed Member of the Board of Directors of Egetis Therapeutics. Prof Sten Nilsson, who has served on the board since 2013, has declined reelection. The decision will be taken at the Annual General Meeting on April 29, and a notice will be sent out separately.
Mats Blom has extensive managerial experience and has held CFO positions in several public and non-public companies, including 9 years at Zealand Pharma A/B, a biotechnology company dually listed on Nasdaq in New York and Copenhagen, and Swedish Orphan International. In addition, he has served as CFO at Modus Therapeutics, Active Biotech AB and Anoto Group AB.
Mats has also worked as a management consultant at Gemini Consulting and Ernst & Young. He holds a BA in Business Administration and Economics from the University of Lund and an MBA from IESE University of Navarra, Barcelona.
Mats is currently the CFO at NorthSea Therapeutics, a biotechnology company in the Netherlands, and board member of Hansa Biopharma and Auris Medical.
“We are incredibly happy to be able attract such a senior professional and executive as Mats to the board. Mats brings substantial experience within corporate governance, finance and the capital markets, establishing subsidiaries in the EU, and doing US listings on Nasdaq. He will definitely add valuable knowledge to Egetis when building an orphan late-stage development company for the future. Sten Nilsson, who has been with the company since 2013, has declined re-election, and I want to thank him for the skilled and invaluable work he has put into the business over this period”, said Kennet Rooth, Chairman of the nomination committee.
